Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
General Internal Medicine
•
Diabetes
•
Gastroenterology
•
Neurology
•
Autonomic Neurology
•
Endocrinology
•
Neuro-Gastroenterology
•
Gastrointestinal Functional & Motility Disorders
Do 5HT4 agonists such as Metoclopramide actually lead to improvement in symptoms for patients with diabetes related gastroparesis?
Related Questions
When and how should we be stopping GLP-1 Receptor Agonist/Dual Agonist therapy?
Do you recommend the use of SGLT2 inhibitors to reduce the risk of liver cirrhosis in patients with Type 2 diabetes mellitus?
Do you recommend routinely monitoring pancreatic markers such as amylase and lipase while receiving GLP1 R agonist or dual agonist therapies to determine their risk of pancreatitis?
What is the optimal BP target for patients with diabetes and hypertension to reduce their risk of MI/stroke?
How do you counsel patients on the use of compounded weight loss medications?
Can rapid weight loss following GLP1 R agonist therapy lead to postprandial hypoglycemia and if so, what are the treatment options outside of dietary modifications?
Is there a role for use of GLP1 R agonist or dual agonist therapy for management of post bariatric hypoglycemia and dumping syndrome?
After what time frame off GLP-1 RA therapy should you restart at the lowest starting dose?
Are recurrent UTIs a contraindication to SGLT2i use?
Do you routinely check vitamin K levels in post-bariatric surgery patients?